We look forward to connecting and learning from other life-science companies at events such as the largest annual Nephrology Congress in Europe, the ERA Congress. Study Director Nephrology Laura Blockken will attend this year’s event, which focuses on recent scientific innovations and important learning features in the clinical field.
InnoSer is invested in supporting the preclinical development of new drugs and therapies for ADPKD (Autosomal Dominant Polycystic Kidney Disease). Laura Blockken is delighted to be discussing the promising effects of direct AMP-activated protein kinase (AMPK) activation with a novel molecule, PXL770, in ADPKD models. Previous research has shown the potential role of reduced AMP-activated protein kinase (AMPK) signalling in the regulation of cyst growth – a strong scientific basis for PXL770 use in ADPKD. At the ERA congress, the most recent preclinical evidence for AMPK activation with this novel compound, both in vitro (canine and human models) and in vivo (mouse model), will be introduced and presented as a mini-oral at the congress.
An Engineered mouse model for PKD drug development
Within the support provided in drug development, InnoSer offers a unique genetically and phenotypically relevant in vivo ADPKD mouse model. Our validated conditional (Tamoxifen) kidney-specific Pkd1 knockout mouse (Pkd1-cKO) models are currently available to meet your individual requirements and scientific questions. Amongst the model options, P18 and P10 are well characterized in our pipelines, and P40 presents an even closer similarity to clinical phenotypes.
- Body weight (monitored daily)
- Kidney weight
- Kidney weight to body weight ratio
- Urea measurement
- Histopathology: cystic index and pathological lesions
- Ultrasound imaging to determine kidney volume
- Multiple well-established models
- AAALAC accredited facilities
- Organ and blood sampling for additional tailored analysis
We are thrilled to be attending this high-quality programme and to get to know other life science enthusiasts – we hope you get in touch with Laura at the ERA congress!
For more information on our In Vivo ADPKD Mouse Model use the button to request the leaflet including our proprietary data.
Curious about more information on our ADPKD model?
Contact an expert for our PKD leaflet including proprietary data.
Want to read more?
Novel Translational Readout: Auditory Event-Related Potentials EEG-Recording in Fragile X Syndrome Model
Fragile X Syndrome Fragile X syndrome is caused by mutations of the FMR1 gene, leading to loss of functional fragile x mental retardation protein (FMRP). FXS is characterised by delays in neurodevelopmental milestones, autistic behaviour, anxiety, and cognitive...
Amyotrophic Lateral Sclerosis (ALS) is a fatal neurodegenerative disorder lacking highly effective disease-modifying treatment or a cure. The often-heterogenous course of ALS underlines the need for modelling the different disease aspects in multiple, distinct models...
In Vitro & In Vivo Parkinson’s Disease Models: Understanding Their Role in Preclinical Drug Development
Parkinson’s disease (PD) is a complex neurodegenerative disorder that affects millions of people worldwide. Different experimental models recapitulate distinct pathophysiological features of PD. Selecting the most appropriate model for a specific research question is...